Cost and cost-effectiveness of antiretroviral therapy for HIV infection in Singapore

被引:9
|
作者
Paton, Nicholas I.
Chapman, Chere A. T.
Sangeetha, S.
Mandalia, Sundhiya
Bellamy, Richard
Beck, Eduard J.
机构
[1] Tan Tock Seng Hosp, Dept Infect Dis, Singapore, Singapore
[2] Chelsea & Westminster Hosp, Imperial Coll London, London, England
[3] Chelsea & Westminster Hosp, NPMS HHC CAC, London, England
[4] McGill Univ, Dept Epidemiol Biostat & Occupat Med, Montreal, PQ, Canada
关键词
cost-effectiveness; antiretroviral therapy; life-year gained; HIV infection;
D O I
10.1258/095646206780071081
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The objective of this study was to determine the cost and cost-effectiveness of antiretroviral therapy (ART) in Singapore. The use and cost of HIV services was calculated for patients managed at the national HIV referral centre in Singapore between 1996 and 2001 from a hospital perspective. Three groups of patients were compared by Centers for Disease Control and Prevention (CDC) stage of HIV infection: those who had never received ART; those who had received only dual therapy; and those who had only received highly active antiretroviral therapy (HAART). Hospital charges were used to estimate the average hospital inpatient and outpatient care costs. Life years gained (LYG) were calculated for different stages of HIV infection and the incremental costs per LYG were calculated comparing those on dual ART and HAART with those who did not receive ART. Patients on ART progressed less rapidly across all CDC stages. For CDC stage A, the incremental cost per LYG was $17,007 (Singaporean dollar) (interquartile range [IQR] $7963-25,113) and $22,511 (IQR $11,299-33,724) for those on dual therapy and HAART, respectively The incremental cost per LYG in stage B was $10,868 (IQR $4506-17,239) and $21,094 (IQR $7774-34,431) for patients on dual therapy and HAART, respectively, while the incremental cost per LYG for stage C patients was $9,848 (IQR $5256-14,419) and $16,513 (IQR $8677-24,337) for dual therapy and HAART, respectively Dual ART therapy and HAART were cost-effective interventions in Singapore. Cost-effectiveness is likely to improve if drug prices continue to decrease.
引用
收藏
页码:699 / 705
页数:7
相关论文
共 50 条
  • [1] Cost-effectiveness of highly active Antiretroviral therapy for HIV infection in Taiwan
    Fang, Chi-Tai
    Chang, Yu-Yin
    Hsu, Hsu-Mei
    Twu, Shiing-Jer
    Chen, Kow-Tong
    Chen, Mao-Yuan
    Huang, Loreen Y. L.
    Hwang, Ling-Shiang
    Wang, Jung-Der
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2007, 106 (08) : 631 - 640
  • [2] The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean
    Wolf, Lindsey L.
    Ricketts, Paul
    Freedberg, Kenneth A.
    Williams-Roberts, Hazel
    Hirschhorn, Lisa R.
    Allen-Ferdinand, Kathleen
    Rodriguez, William R.
    Divi, Nomita
    Wong, Michael T.
    Losina, Elena
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (04) : 463 - 471
  • [3] Cost-Effectiveness of Antiretroviral Therapy for Prevention
    Kahn, James G.
    Marseille, Elliot A.
    Bennett, Rod
    Williams, Brian G.
    Granich, Reuben
    [J]. CURRENT HIV RESEARCH, 2011, 9 (06) : 405 - 415
  • [4] Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy
    Sanders, GD
    Bayoumi, AM
    Sundaram, V
    Bilir, SP
    Neukermans, CP
    Rydzak, CE
    Douglass, LR
    Lazzeroni, LC
    Holodniy, M
    Owens, DK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (06): : 570 - 585
  • [5] Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study
    Slot, Matilde
    Rasmussen, Thomas Bojer
    Norgaard, Mette
    Larsen, Carsten Schade
    Ehlers, Lars Holger
    [J]. PHARMACOECONOMICS-OPEN, 2024,
  • [6] Cost-Effectiveness of Antiretroviral Therapy: A Systematic Review
    Gupta, Indrani
    Singh, Damini
    [J]. INDIAN JOURNAL OF PUBLIC HEALTH, 2020, 64 : 32 - 38
  • [7] Cost-Effectiveness of Generic Antiretroviral Therapy RESPONSE
    Walensky, Rochelle P.
    Paltiel, A. David
    Schackman, Bruce R.
    [J]. ANNALS OF INTERNAL MEDICINE, 2013, 158 (10) : 776 - 777
  • [8] Relationship between adherence to antiretroviral therapy and the cost-effectiveness of antiretroviral therapy
    Habib, M. J.
    Lawson, K.
    Summers, K. K.
    Eakin, R. T.
    Barner, J.
    Brown, C.
    Shepherd, M. D.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A206 - A206
  • [9] Cost-effectiveness of directly observed highly active antiretroviral therapy in pregnant women with asymptomatic HIV infection
    Fisman, D
    Cosgrove, SE
    Perencevich, EN
    Levy, DB
    Goldie, S
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1224 - 1224
  • [10] Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies
    Ouattara, Eric N.
    Robine, Marion
    Eholie, Serge P.
    MacLean, Rachel L.
    Moh, Raoul
    Losina, Elena
    Gabillard, Delphine
    Paltiel, A. David
    Danel, Christine
    Walensky, Rochelle P.
    Anglaret, Xavier
    Freedberg, Kenneth A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2016, 62 (11) : 1454 - 1462